Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons

European Journal of Neuroscience

Volumn 29, Issue 3, 2009, Pages 455-464

  Melo, Joana B ^a,b   Sousa, Carla ^a,b   Garção, Pedro ^a,b   Oliveira, Catarina R ^a,b   Agostinho, Paula ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Amyloid aggregates; Antioxidant defenses; Galantamine; Neurodegeneration; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; GALANTAMINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LIPID; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN NERVE CELL; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; FIBER; IN VITRO STUDY; LIPID PEROXIDATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; GLUTATHIONE; LIPID PEROXIDATION; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RATS; SENILE PLAQUES;

EID: 59149090400     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2009.06612.x     Document Type: Article

References (64)

1. Agostinho, P. Oliveira, C.R. (2003) Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides. Eur. J. Neurosci., 17, 1189 1196.
2. Aksenov, M.Y. Markesbery, W.R. (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci. Lett., 302, 141 145.
3. Aksenov, M.Y., Tucker, H.M., Nair, P., Aksenova, M.V., Butterfield, D.A., Estus, S. Markesbery, W.R. (1998) The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J. Mol. Neurosci., 11, 51 164.
4. Arias, E., Alés, E., Gabilan, N.H., Cano-Abad, M.F., Villarroya, M., Garcia, A.G. López, M.G. (2004) Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology, 46, 103 114.
5. Arias, E., Gallego-Sandín, S., Villarroya, M., Garcia, A.G. López, M.G. (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther., 315, 1346 1353.
6. Barik, J., Dajas-Bailador, F. Wonnacott, S. (2005) Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. Br. J. Pharmacol., 145, 1084 1092.
7. Bartolini, M., Bertucci, C., Cavrini, C. Andrisano, V. (2003) β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 65, 407 416.
8. Blennow, K., de Leon, M.J. Zetterberg, H. (2006) Alzheimer's disease. Lancet, 368, 387 403.
9. Butterfield, D.A. (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res., 36, 1307 1313.
10. Casado, A., Encarnación López-Fernández, M., Concepción Casado, M. de La Torre, R. (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res., 33, 450 458.
11. Chauhan, V. Chauhan, A. (2006) Oxidative stress in Alzheimer's disease. Pathophysiology, 13, 195 208.
12. Chen, K., Maley, J. Yu, P.H. (2006) Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J. Neurochem., 99, 1413 1424.
13. Coyle, J.T., Geerts, H., Sorra, K. Amatniek, J. (2007) Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J. Alzheimers Dis., 11, 491 507.
14. De Felice, F.G., Vieira, M.N., Saraiva, L.M., Figueroa-Villar, J.D., Garcia-Abreu, J., Liu, R., Chang, L., Klein, W.L. Ferreira, S.T. (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J., 18, 1366 1372.
15. Deshpande, A., Mina, E., Glabe, C. Busciglio, J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci., 26, 6011 6018.
16. Duarte, A.I., Santos, M.S., Oliveira, C.R. Rego, A.C. (2005) Insulin neuroprotection against oxidative stress in cortical neurons: involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med., 39, 876 889.
17. Dumont, M., Lalonde, R., Ghersi-Egea, J.F., Fukuchi, K. Strazielle, C. (2006) Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP. J. Neural Transm., 113, 1225 1241.
18. Ellman, G.L., Courtney, K.D., Andres, V. Jr. Feather-Stone, R.M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88 95.
19. Ezoulin, M.J., Ombetta, J.E., Dutertre-Catella, H., Warnet, J.M. Massicot, F. (2008) Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology, 29, 270 277.
20. Ferreiro, E., Resende, R., Costa, R., Oliveira, C.R. Pereira, C.M. (2006) An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis., 23, 669 678.
21. Fodero, L.R., Mok, S.S., Losic, D., Martin, L.L., Aguilar, M.I., Barrow, C.J., Livett, B.G. Small, D.H. (2004) Alpha7-nicotinic acetylcholine receptors mediate an Abeta (1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J. Neurochem., 88, 1186 1193.
22. Geerts, H. (2005) Indicators of neuroprotection with galantamine. Brain Res. Bull., 64, 519 524.
23. Geerts, H., Guillaumat, P.O., Grantham, C., Bode, W., Anciaux, K. Sachak, S. (2005) Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res., 1033, 186 193.
24. Haass, C. Selkoe, D.J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 8, 101 112.
25. Hager, K., Kenklies, M., McAfoose, J., Engel, J. Münch, G. (2007) Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J. Neural Transm. Suppl., 72, 189 193.
26. Heinitz, K., Beck, M., Schliebs, R. Perez-Polo, J.R. (2006) Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergicSN56.B5.G4 cells. J. Neurochem., 98, 1930 1945.
27. Hu, W., Gray, N.W. Brimijoin, S. (2003) Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem., 86, 470 478.
28. Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A. Shimohama, S. (2004) Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 325, 976 982.
29. Klein, W.L., Stine, W.B. Jr. Teplow, D.B. (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging, 25, 569 580.
30. Koppaka, V., Paul, C., Murray, I.V. Axelsen, P.H. (2003) Early synergy between Abeta42 and oxidatively damaged membranes in promoting amyloid fibril formation by Abeta40. Biol. Chem., 278, 36277 36284.
31. Kremer, J.J. Murphy, R.M. (2003) Kinetics of adsorption of beta-amyloid peptide Abeta(1-40) to lipid bilayers. J. Biochem. Biophys. Methods, 57, 159 169.
32. Lenzken, S.C., Lanni, C., Govoni, S., Lucchelli, A., Schettini, G. Racchi, M. (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem. Biol. Interact., 165, 138 145.
33. Lin, H., Bhatia, R. Lal, R. (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J., 15, 2433 2444.
34. Liu, L., Komatsu, H., Murray, I.V. Axelsen, P.H.J. (2008) Promotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product. Mol. Biol., 377, 1236 1250.
35. Lorrio, S., Sobrado, M., Árias, E., Roda, J.M., Garcia, A.G. López, M.G. (2007) Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther., 322, 591 599.
36. Lovell, M.A. Markesbery, W.R. (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res., 85, 3036 3040.
37. Maezawa, I., Hong, H.S., Liu, R., Wu, C.Y., Cheng, R.H., Kung, M.P., Kung, H.F., Lam, K.S., Oddo, S., Laferla, F.M. Jin, L.W. (2008) Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem., 104, 457 468.
38. Mancuso, C., Bates, T.E., Butterfield, D.A., Calafato, S., Cornelius, C., De Lorenzo, A., Dinkova Kostova, A.T. Calabrese, V. (2007) Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs, 16, 1921 1931.
39. Melo, J.B., Agostinho, P. Oliveira, C.R. (2003) Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res., 45, 117 127.
40. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55 63.
41. Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M. Matsuzaki, K. (2008) Formation of toxic Abeta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in Abeta(1-40) fibrils. J. Mol. Biol., 382, 1066 1074.
42. Ono, K., Hamaguchi, T., Naiki, H. Yamada, M. (2006) Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim. Biophys. Acta, 1762, 575 586.
43. Pereira, C., Agostinho, P., Moreira, P.I., Cardoso, S.M. Oliveira, C.R. (2005) Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr. Drug Targets CNS Neurol. Disord., 4, 383 403.
44. Prediger, R.D., Franco, J.L., Pandolfo, P., Medeiros, R., Duarte, F.S., Di Giunta, G., Figueiredo, C.P., Farina, M., Calixto, J.B., Takahashi, R.N. Dafre, A.L. (2007) Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav. Brain Res., 177, 205 213.
45. Puchtler, H., Waldrop, F.S. Meloan, S.N. (1985) A review of light, polarization and fluorescence microscopic methods for amyloid. Appl. Pathol., 3, 5 17.
46. Resende, R., Moreira, P.I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C. Oliveira, C.R. (2008) Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic. Biol. Med., 44, 2051 2057.
47. Reyes, A.E., Chacón, M.A., Dinamarca, M.C., Cerpa, W., Morgan, C. Inestrosa, N.C. (2004) Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am. J. Pathol., 164, 2163 2174.
48. Sáez-Valero, J., Fodero, L.R., White, A.R., Barrow, C.J. Small, D.H. (2003) Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with beta-amyloid peptides. Brain Res., 965, 283 286.
49. Santos, M.D., Alkondon, M., Pereira, E.F., Aracava, Y., Eisenberg, H.M., Maelicke, A. Albuquerque, E.X. (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol., 61, 1222 1234.
50. Sberna, G., Sáez-Valero, J., Li, Q.X., Czech, C., Beyreuther, K., Masters, C.L., McLean, C.A. Small, D.H. (1998) Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimers disease. J. Neurochem., 71, 723 731.
51. Schuessel, K., Leutner, S., Cairns, N.J., Müller, W.E. Eckert, A. (2004) Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J. Neural Transm., 1, 1167 1182.
52. Selkoe, D.J. (2001) Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA, 98, 11039 11041.
53. Sies, H. (1999) Glutathione and its role in cellular functions. Free Radic. Biol. Med., 27, 916 921.
54. Sponne, I., Fifre, A., Drouet, B., Klein, C., Koziel, V., Pinçon-Raymond, M., Olivier, J.L., Chambaz, J. Pillot, T. (2003) Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem., 278, 3437 3445.
55. Sung, S., Yao, Y., Uryu, K., Yang, H., Lee, V.M., Trojanowski, J.Q. Praticò, D. (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J., 18, 323 325.
56. Tabner, B.J., El-Agnaf, O.M., Turnbull, S., German, M.J., Paleologou, K.E., Hayashi, Y., Cooper, L.J., Fullwood, N.J. Allsop, D. (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer's disease and familial British dementia. J. Biol. Chem., 280, 35789 35792.
57. Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O. Tabaton, M. (2006) The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med., 41, 202 212.
58. Tamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., Muraca, G., Danni, O., Zhu, X., Smith, M.A., Perry, G., Jo, D.G., Mattson, M.P. Tabaton, M. (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J. Neurochem., 104, 683 695.
59. Traykova, M., Traykov, T., Hadjimitova, V., Krikorian, K. Bojadgieva, N. (2003) Antioxidant properties of galantamine hydrobromide. Z. Naturforsch. [C], 58, 361 365.
60. Unger, C., Svedberg, M.M., Yu, W.F., Hedberg, M.M. Nordberg, A. (2006) Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. J. Pharmacol. Exp. Ther., 317, 30 36.
61. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M. Telser, J. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 39, 44 84.
62. Woltjer, R.L., Nghiem, W., Maezawa, I., Milatovic, D., Vaisar, T., Montine, K.S. Montine, T.J. (2005) Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J. Neurochem., 93, 1047 1056.
63. Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G., Frautschy, S.A. Cole, G.M. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 280, 5892 5901.
64. Zhang, Q., Powers, E.T., Nieva, J., Huff, M.E., Dendle, M.A., Bieschke, J., Glabe, C.G., Eschenmoser, A., Wentworth, P. Jr., Lerner, R.A. Kelly, J.W. (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc. Natl Acad. Sci. USA, 101, 4752 4757.